English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death (1). Eighty to eighty-five percent of lung cancer cases are NSCLC (1). Because the lack of cancer-specific symptoms, the majority of NSCLC cases are diagnosed at advanced stage, which always results in poor prognosis of patients with NSCLC (2). Because 10–35% NSCLCs are driven by epidermal growth factor receptor (EGFR) mutations, EGFR has emerged as the most successive target for NSCLC therapy (3). However, only a limited subset of patients harboring EGFR mutations benefit from the EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy, the majority of NSCLC patients Original Article

A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib